The PRIME-ROSE consortium will be present at two major oncology events this autumn: ESMO MAP in Paris (held 15–16 September) and the ESMO Congress 2025 in Berlin (17–21 October). These events will progress significantly the consortium’s mission to advance precision cancer medicine through pragmatic clinical trials and cross-border collaboration.

‍

🧬 Highlights from ESMO MAP 2025

At the ESMO MAP Congress in Paris, PRIME-ROSE partners will showcase molecular insights and trial expansions:

• ProTarget Study:
      Investigating BRAF-Targeted Therapies in Cancers Beyond Melanoma and     Colorectal Cancer
      🎤 L. Belcaid, T. Kringelbach, K. Rohrberg     and colleagues

•  ProTarget Study:
  Exploring new opportunities for ERBB2 (HER2) targeted therapies beyondconventional cancer types
  🎤 L. Belcaid, C. Secher, K. Egebjerg and team

·

‍🔬 Scientific Contributions at ESMO 2025

Consortium members will present a wide range of research findings and policy insights:

‍

Mini Oral & Proffered Paper Sessions

• 1140MO – Clinical benefit of genomic-guided targeted therapies in patients with rare cancers: First results from the IMPRESS-Norway trial
      🎤 Katarina Puco (Oslo, Norway)
• 2273O – Routes for access to off-label treatments: a comparative analysis of 19 European countries
      🎤 Atse Huisman (Leiden, The Netherlands)
• 3137O – IMPRESS-Norway: A Nationwide Precision-Oncology Study for Off-Label Targeted Therapies: Results From the First 1,740 Patients
      🎤 Sigmund Brabrand (Oslo, Norway)

‍

Young Oncologists Brunch

• Drug repurposing trials: What are they and where are they going?
      🎤     Kjetil Taskén (Oslo, Norway)

‍

Poster Presentations

• Ingrid Dyvik, Soemeya F. Haj Mohammad, Hans Timmer, Tina Kringelbach, Henk van der Pol and others will present results from IMPRESS-Norway, DRUP, ProTarget trials, which all are collaborating with PRIME-ROSE.

‍

These presentations reflect the consortium’s commitment to expanding the therapeutic landscape for patients with rare or refractory cancers.

‍

The PRIME-ROSE team has  already planned many collaboration meetings both with Pharma and research colleagues. These meetings will foster collaboration and strengthen the growing community of precision oncology researchers.

‍

📢 PRIME-ROSE aims to:

• Promote pragmatic clinical trials and real-world evidence generation
• Harmonize access to off-label treatments across Europe
• Engage stakeholders including regulators, patient organizations, and industry

‍